J Michael Soucie

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11281246/publications.pdf

Version: 2024-02-01

48 papers	4,511 citations	257450 24 h-index	206112 48 g-index
49 all docs	49 docs citations	49 times ranked	2897 citing authors

#	Article	IF	Citations
1	Occurrence rates of inherited bleeding disorders other than haemophilia and von Willebrand disease among people receiving care in specialized treatment centres in the United States. Haemophilia, 2022, 28, .	2.1	3
2	Characteristics, complications, and sites of bleeding among infants and toddlers less than 2 years of age with VWD. Blood Advances, 2021, 5, 2079-2086.	5.2	4
3	Women and girls with haemophilia receiving care at specialized haemophilia treatment centres in the United States. Haemophilia, 2021, 27, 1037-1044.	2.1	14
4	Hemophilia without prophylaxis: Assessment of joint range of motion and factor activity. Research and Practice in Thrombosis and Haemostasis, 2020, 4, 1035-1045.	2.3	3
5	Evaluation of CDCâ€™s Hemophilia Surveillance Program â€" Universal Data Collection (1998â€"2011) and Community Counts (2011â€"2019), United States. MMWR Surveillance Summaries, 2020, 69, 1-18.	34.6	26
6	Executive summary of the NHLBI State of the Science (SOS) Workshop: Overview and next steps in generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 610-615.	2.1	8
7	Origins and organization of the NHLBI State of the Science Workshop: Generating a national blueprint for future research on factor VIII inhibitors. Haemophilia, 2019, 25, 575-580.	2.1	6
8	Potential of the Community Counts registry to characterize rare bleeding disorders. Haemophilia, 2019, 25, 1045-1050.	2.1	11
9	Factor VIII prophylaxis effects outweigh other hemostasis contributors in predicting severe haemophilia A joint outcomes. Haemophilia, 2019, 25, 867-875.	2.1	8
10	Global Hemophilia Care: Data for Action. Annals of Internal Medicine, 2019, 171, 585.	3.9	5
11	Relevance of Abusive Head Trauma to Intracranial Hemorrhages and Bleeding Disorders. Pediatrics, 2018, 141, e20173485.	2.1	15
12	The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B. Blood Advances, 2018, 2, 2136-2144.	5.2	69
13	Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood, 2017, 129, 2368-2374.	1.4	121
14	Men with severe hemophilia in the United States: birth cohort analysis of a large national database. Blood, 2016, 127, 3073-3081.	1.4	93
15	Characteristics of hemophilia patients with factor <scp>VIII</scp> inhibitors detected by prospective screening. American Journal of Hematology, 2015, 90, 871-876.	4.1	11
16	Impact of inhibitors on hemophilia a mortality in the <scp>U</scp>nited <scp>S</scp>tates. American Journal of Hematology, 2015, 90, 400-405.	4.1	127
17	A Public Health Approach to the Prevention of Inhibitors in Hemophilia. American Journal of Preventive Medicine, 2014, 47, 669-673.	3.0	10
18	The national haemophilia program standards, evaluation and oversight systems in the United States of America. Blood Transfusion, 2014, 12 Suppl 3, e542-8.	0.4	3

#	Article	IF	Citations
19	Evidence for the transmission of parvovirus B19 in patients with bleeding disorders treated with plasmaâ€derived factor concentrates in the era of nucleic acid test screening. Transfusion, 2013, 53, 1217-1225.	1.6	40
20	The CDC Hemophilia A Mutation Project (CHAMP) Mutation List: A New Online Resource. Human Mutation, 2013, 34, E2382-E2392.	2.5	52
21	The effect of secondary prophylaxis versus episodic treatment on the range of motion of target joints in patients with haemophilia. British Journal of Haematology, 2013, 161, 424-433.	2.5	21
22	Public health surveillance and data collection: general principles and impact on hemophilia care. Hematology, 2012, 17, s144-s146.	1.5	28
23	High oneÂyear mortality in adults with sickle cell disease and endâ€stage renal disease. British Journal of Haematology, 2012, 159, 360-367.	2.5	100
24	A study of variations in the reported haemophilia B prevalence around the world. Haemophilia, 2012, 18, e91-4.	2.1	93
25	Prevalence of malignancies among U.S. male patients with haemophilia: a review of the Haemophilia Surveillance System. Haemophilia, 2012, 18, 532-539.	2.1	20
26	Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database. Haemophilia, 2012, 18, e260-5.	2.1	45
27	Physical Functioning in Boys with Hemophilia in the U.S.. American Journal of Preventive Medicine, 2011, 41, S360-S368.	3.0	35
28	Knowledge and Therapeutic Gaps. American Journal of Preventive Medicine, 2011, 41, S324-S331.	3.0	13
29	Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States. British Journal of Haematology, 2011, 152, 211-216.	2.5	98
30	Pediatric Hemophilia: A Review. Seminars in Thrombosis and Hemostasis, 2011, 37, 737-744.	2.7	56
31	A study of variations in the reported haemophilia A prevalence around the world. Haemophilia, 2010, 16, 20-32.	2.1	224
32	Burden of Disease Resulting from Hemophilia in the U.S.. American Journal of Preventive Medicine, 2010, 38, S482-S488.	3.0	25
33	Assessing Emerging Infectious Threats to Blood Safety for the Blood Disorders Community. American Journal of Preventive Medicine, 2010, 38, S468-S474.	3.0	14
34	The Universal Data Collection Surveillance System for Rare Bleeding Disorders. American Journal of Preventive Medicine, 2010, 38, S475-S481.	3.0	54
35	High School Completion Rates Among Men with Hemophilia. American Journal of Preventive Medicine, 2010, 38, S489-S494.	3.0	16
36	Increased Prevalence of Inhibitors in Mexican-Hispanic Patients with Severe Hemophilia A Enrolled in the Universal Data Collection Project.. Blood, 2009, 114, 3488-3488.	1.4	2

#	Article	IF	Citations
37	Septic arthritis in males with haemophilia. Haemophilia, 2008, 14, 494-503.	2.1	24
38	Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. New England Journal of Medicine, 2007, 357, 535-544.	27.0	1,681
39	Prevalence and risk factors for heart disease among males with hemophilia. American Journal of Hematology, 2005, 79, 36-42.	4.1	115
40	Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood, 2004, 103, 2467-2473.	1.4	225
41	Human parvovirus B19 in young male patients with hemophilia A: associations with treatment product exposure and joint range-of-motion limitation. Transfusion, 2004, 44, 1179-1185.	1.6	24
42	Renal disease among males with haemophilia. Haemophilia, 2003, 9, 703-710.	2.1	84
43	Vascular access and increased risk of death among hemodialysis patients. Kidney International, 2002, 62, 620-626.	5.2	395
44	Changes in the occurrence of and risk factors for hemophilia-associated intracranial hemorrhage. American Journal of Hematology, 2001, 68, 37-42.	4.1	89
45	Epidemiology of Device-Associated Infections Related to a Long-Term Implantable Vascular Access Device. Infection Control and Hospital Epidemiology, 1999, 20, 187-191.	1.8	57
46	Occurrence of hemophilia in the United States. , 1998, 59, 288-294.		288
47	Facility Mortality Rates for New End-Stage Renal Disease Patients: Implications for Quality Improvement. American Journal of Kidney Diseases, 1994, 24, 280-289.	1.9	24
48	A Prospective Comparison of Methods for Determining if Cardiovascular Disease is a Predictor of Mortality in Dialysis Patients. American Journal of Kidney Diseases, 1994, 23, 382-388.	1.9	28